RCS - Faron Pharma. Oy - Traumakine Research Collaboration and DoD Grant

Faron Pharmaceuticals OyAnnouncement

13/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240813:nRSM1464Aa&default-theme=true

RNS Number : 1464A  Faron Pharmaceuticals Oy  13 August 2024

Faron Pharmaceuticals Ltd.

 

("Faron" or the "Company")

 

 

Faron Announces Traumakine Research Collaboration and DoD Grant

 

Press release, 13 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST

 

TURKU, Finland - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company with its lead immune oncology program
bexmarilimab, also pursuing induction of CD73 for organ protection, announces
it has joined a research consortium that has received a Department of Defense
(DoD) Grant to investigate the use of intravenous interferon beta
(TraumakineÒ) for the prevention of ischemia-reperfusion injury in
battlefield victims when using a lifesaving torniquet for the prevention of
excessive blood loss. The Study is named Resuscitation by Endothelial
Stabilization and Targeted Oxygen Rescue (RESTOR) Platform for Battlefield
Applications. Participating institutions are Duquesne University School of
Pharmacy and Wake Forest Medical University Health Sciences.

 

As previously investigated under another DoD grant by the same team,
TraumakineÒ was highly effective for limb salvage and prevention of systemic
inflammation and organ damage when given at the time of placing the torniquet,
but not when given later. In the current setting TraumakineÒ will be
investigated when given as a preventative treatment prior to placing the
torniquet, simulating a situation where operational units going into a mission
would be pre-treated with TraumakineÒ before going into combat where injury
could result in the need for a torniquet. The aim of TraumakineÒ in this
setting would be to improve survival and limb salvage by attenuating
ischemia-reperfusion injury if a torniquet was needed.

 

If the results of these upcoming pre-clinical experiments are positive, this
could open an avenue for approval without extensive human clinical studies. In
conditions where controlled clinical studies cannot be conducted, a drug could
be approved by using pre-clinical studies simulating the intended use. As a
widely used and well tolerated drug with a large amount of human exposure,
interferon beta could potentially qualify as such a drug. Previous examples of
such approvals also relate to defense, where the investigational drug cannot
be tested in humans in the desired indication, but is proven to be safe in man
while the efficacy is proven based on the mode of action and pre-clinical
studies.

 

"We are very pleased to see the DoD's continued support to this research group
and the TraumakineÒ program. From our learnings from previous clinical trials
with TraumakineÒ, we envision that the best outcomes with intravenous
interferon beta can be achieved when the drug is used for the prevention, and
not necessarily treatment, of systemic inflammation and organ damage. RESTOR
is a pilot study to test TraumakineÒ in this preventative setting, and paid
by the DoD, but if positive, it could bolster Traumakine'sÒ path to market in
this setting, and the Company should consider investing further into the
program or find a partner for it." said Dr. Juho Jalkanen, Chief Executive
Officer of Faron.

 

For more information on research collaboration, please visit: Duquesne
Receives New $1.5 Million Grant to Expand Transplantation Research
(https://www.duq.edu/news-and-stories/releases/drj-dodgrant.php)

 

 

For more information please contact:

 

Investor Contact

 

Media Contact

ICR Consilium

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com (mailto:faron@consilium-comms.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

 

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at www.faron.com
(http://www.faron.com) .

 

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be,
forward-looking statements. Forward looking statements are identified by their
use of terms and phrases such as ''believe'', ''could'', "should", "expect",
"hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'',
''potentially'', ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions. These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the
results and expectations discussed in the forward-looking statements, many of
which are beyond the control of the Company. In addition, other factors which
could cause actual results to differ materially include the ability of the
Company to successfully license its programs within the anticipated timeframe
or at all, risks associated with vulnerability to general economic and
business conditions, competition, environmental and other regulatory changes,
actions by governmental authorities, the availability of capital markets or
other sources of funding, reliance on key personnel, uninsured and
underinsured losses and other factors. Although any forward-looking statements
contained in this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that actual
results will be consistent with such forward-looking statements. Accordingly,
readers are cautioned not to place undue reliance on forward-looking
statements. Subject to any continuing obligations under applicable law or any
relevant AIM Rule requirements, in providing this information the Company does
not undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events, conditions or
circumstances on which any such statement is based.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFLFMEELSEFA